Modality
ERT
MOA
STINGag
Target
CD38
Pathway
PI3K/AKT
PSPPsA
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
May 2022
→ Sep 2029
Phase 1Current
NCT06367714
454 pts·PsA
2022-05→2029-09·Completed
NCT07287396
189 pts·PsA
2022-09→2027-12·Terminated
643 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-281.7y awayInterim· PsA
2029-09-173.5y awayInterim· PsA
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Complet…
P1
Termina…
Catalysts
Interim
2027-12-28 · 1.7y away
PsA
Interim
2029-09-17 · 3.5y away
PsA
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06367714 | Phase 1 | PsA | Completed | 454 | Safety |
| NCT07287396 | Phase 1 | PsA | Terminated | 189 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |